Tag - Raju Prasad


WB starts Arcellx at OP; fair value estimate $40

William Blair initiated coverage of Arcellx (NASDAQ:ACLX) with an “outperform” rating and fair value estimate of $40. The stock closed at $16.94 on Feb. 28. Arcellx’s next-generation cell therapy platform is founded on...

Generation Bio

WB cuts Generation Bio to market perform

William Blair downgraded Generation Bio (NASDAQ:GBIO) to “market perform,” citing variability in a non-human primate study in Factor VIII production for its hemophilia program.  In mid-morning trading, the stock was...

Assembly Biosciences

WB cuts Assembly Biosciences to MP from OP

William Blair downgraded Assembly Biosciences (NASDAQ:ASMB) to “market perform” from “outperform” after the company discontinued clinical development of ABI-H2158, its second-generation core inhibitor for the treatment...

Selecta Biosciences

WB ups Selecta Biosciences to outperform

William Blair upgraded Selecta Biosciences (NASDAQ:SELB) to “outperform,” citing multiple upcoming positive risk/reward catalysts for the company. The stock closed at $3.90 on March 11. The company’s ImmTOR platform...